Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA (FME.XETRA) — 5‑year timeline (2021–2026). Latest price (2026‑07‑01): 39.6

2021

COVID‑19 suppressed dialysis volumes and elevated patient mortality; FY‑2021 disclosures quantified excess mortality at approximately 9,800 for the year and roughly 20,100 since the pandemic began. The company reiterated its medium‑term 2025 targets at the AGM and pressed ahead with the FME25 transformation program, targeting approximately €500m in savings by 2025, while continuing to raise dividends. [1,9,4]

Investors began recognizing the stock's pronounced sensitivity to patient volumes and near‑term earnings risk, even as the defensive healthcare narrative held. Year‑end close of €57.14 marked a −16% decline for 2021, with price action remaining compressed throughout the year. [13]

2022 (H1)

Russia's invasion of Ukraine in February directly disrupted operations in those markets. Q1‑2022 contained special‑item impacts of approximately €22m on operating income alongside COVID‑related excess mortality. Inflation, supply‑chain disruption and U.S. labor shortages materially raised costs and compressed margins. Rice Powell's retirement was announced with Carla Kriwet named successor on May 3, 2022. The company adjusted its outlook in response to the deteriorating macro environment. [34,30,32,16]

The narrative shifted from "defensive compounder" to a story centered on macro headwinds and earnings risk. Investors focused on inflation, staffing costs and the Ukraine war's operational impact, while succession news heightened scrutiny on governance and execution. [30,31,16]

A strong early‑2022 rally peaked above €62 in spring, with a high of €63.56 on April 21, 2022, before a sharp multi‑month decline as macro and operational pressures crystallized. [30]

2022 (H2) → late 2022

Rice Powell stepped down at end‑September 2022, with Dr. Carla Kriwet assuming the role on October 1 but resigning December 5, 2022. Helen Giza, previously CFO, Deputy CEO and CTO for FME25, was appointed CEO effective December 6, 2022. Persistent inflation and labor cost pressures reduced both operating and net income for the full year. [16,17,18,19,30,39]

Management instability combined with ongoing cost inflation reinforced an "execution‑risk / value‑trap" perception; investor focus moved to whether mid‑term cost savings could materialize and debt could be reduced. [18,30]

The downtrend and elevated volatility persisted into late‑2022; the share price fell significantly from the April high and failed to recover during the remainder of the year. [30]

2023

Strategic Portfolio Optimization accelerated: Argentina operations were sold to Grupo Olmos, the National Cardiovascular Partners outpatient network closed in December, and Cura Day Hospitals was sold to ICG (subject to approvals). Divestments closed in 2023 represented approximately €214m in pro‑forma revenue and approximately €20m in operating income; the company expected approximately €500m in net proceeds (approximately €135m in Q4‑2023, with the remainder in 2024) and recognized an estimated net‑book loss of approximately €50m as a Q4‑2023 special item. The company also changed its legal form following shareholder approval on July 14, 2023 (change entered the commercial register November 30, 2023) and was de‑consolidated from parent Fresenius, which retained approximately 32% stake. A non‑global dialysis cycler program was discontinued. [3,48,50,54,56]

The narrative shifted toward "turnaround and portfolio‑rationalization." Investors began to reward de‑risking and explicit deleveraging plans, though caution persisted because divestments trimmed revenue and generated one‑time charges. The market awaited clear FME25 delivery and sustained organic recovery. [3,50,54]

Trading remained volatile and largely range‑bound, with relief rallies around confirmed divestments and legal‑form milestones, but no sustained return to 2022 highs. Price action reflected transition risk and one‑off impacts. [48,50,3]

2024

The company reported continued execution of portfolio optimization and directed proceeds toward deleveraging (January 8, 2024). Management refined segment structures with Care Delivery leadership changes effective January 1, 2024. FME25 savings and transformation efforts advanced. [3,25,27]

Perception steadily shifted toward "operational turnaround and margin recovery" as execution and deleveraging gained visible traction, though investors still required recurring evidence of cash flow and margin improvement before a full re‑rating. [3,6]

Partial recovery attempts occurred across 2024 driven by execution headlines; however the price remained materially below the April‑2022 high of €63.56 and faced retests of prior resistance and support levels. [3,6,30]

2025 → mid‑2026

The company reported 18% earnings growth for 2024 (February 25, 2025) and provided 2025 guidance of revenue positive to low‑single‑digit growth, with operating‑income growth expected in the high‑teens to high‑twenties percent range. On February 24, 2025, it signed an agreement for Quest Diagnostics to acquire select laboratory assets, continuing portfolio optimization. Management signaled FME25 savings ahead of schedule and maintained focus on deleveraging and capital allocation. [6,8,3]

The narrative centered on "proof‑of‑execution" — earnings and margin improvement validated the earlier strategic moves. Investors balanced that against reduced revenues from exits, structural reimbursement and market risks, and broader macro headwinds with multiple compression. Market emphasis shifted to sustainable free cash flow and deleveraging. [6,3,8]

Short‑term rallies accompanied the 2024 results and asset‑sale announcements; broader re‑rating remained constrained by macro conditions and multiple compression. As of mid‑2026, the stock trades at 39.6, consolidated and discounted versus 2021–22 peaks and remaining below the April‑2022 high of €63.56. [6,3,30]